Calibration of cell-free DNA measurements by next-generation sequencing
American Journal of Clinical Pathology · 2023
DOI: 10.1093/ajcp/aqad055 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2023. Verfasst von Derek Hoerres und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, US. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
Objectives
Accurate monitoring of disease burden depends on accurate disease marker quantification. Although next-generation sequencing (NGS) is a promising technology for noninvasive monitoring, plasma cell-free DNA levels are often reported in misleading units that are confounded by non–disease-related factors. We proposed a novel strategy for calibrating NGS assays using spiked normalizers to improve precision and to promote standardization and harmonization of analyte concentrations.
Methods
In this study, we refined our NGS protocol to calculate absolute analyte concentrations to (1) adjust for assay efficiency, as judged by recovery of spiked synthetic normalizer DNAs, and (2) calibrate NGS values against droplet digital polymerase chain reaction (ddPCR). As a model target, we chose the Epstein-Barr virus (EBV) genome. In patient (n = 12) and mock (n = 12) plasmas, NGS and 2 EBV ddPCR assays were used to report EBV load in copies per mL of plasma.
Results
Next-generation sequencing was equally sensitive to ddPCR, with improved linearity when NGS values were normalized for spiked DNA read counts (R2 = 0.95 for normalized vs 0.91 for raw read concentrations). Linearity permitted NGS calibration to each ddPCR assay, achieving equivalent concentrations (copies/mL).
Conclusions
Our novel strategy for calibrating NGS assays suggests potential for a universal reference material to overcome biological and preanalytical variables hindering traditional NGS strategies for quantifying disease burden.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, US.
- Lineberger Comprehensive Cancer Center, Chapel Hill, NC, US.
- Division of Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, US.
- Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, US.
ORCID-Profile: Derek Hoerres
Förderung
- NCATS NIH HHS
- NCI NIH HHS
- NIH HHS
- National Center for Advancing Translational Sciences
- National Cancer Institute
- University of North Carolina
- Translational Science Center
- NIH
Zitieren
APA
Hoerres, D., Dai, Q., Elmore, S., Sheth, S., Gupta, G. P., Kumar, S., & Gulley, M. L. (2023). Calibration of cell-free DNA measurements by next-generation sequencing. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqad055
Vancouver
Hoerres D, Dai Q, Elmore S, Sheth S, Gupta GP, Kumar S, et al. Calibration of cell-free DNA measurements by next-generation sequencing. American Journal of Clinical Pathology. 2023. doi:10.1093/ajcp/aqad055
BibTeX
@article{Hoerres2023,
author = {Hoerres, Derek and Dai, Qunsheng and Elmore, Sandra and Sheth, Siddharth and Gupta, Gaorav P and Kumar, Sunil and Gulley, Margaret L},
title = {Calibration of cell-free DNA measurements by next-generation sequencing},
journal = {American Journal of Clinical Pathology},
year = {2023},
doi = {10.1093/ajcp/aqad055}
}
EUVIMED